Key terms
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRKR news
Apr 08
12:07pm ET
Marker Therapeutics’ MT-601 Shows Promising Results
Apr 08
7:14am ET
Marker Therapeutics announces presentation on Phase 1 APOLLO study
Mar 26
1:07pm ET
Marker Therapeutics Advances in Immuno-Oncology
Mar 01
8:12am ET
Marker Therapeutics Ends Stock Sale Deal with LPC
Jan 22
7:35am ET
Marker receives approval from the USAN council, INN committee for neldaleucel
MRKR Financials
Key terms
Ad Feedback
MRKR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRKR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
